151224-83-8c1cc(-c2nc3c4c(ncc3[nH]2)CCOC4)no1ITPFSYAYHHPKRT-UHFFFAOYSA-NS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
151224-83-8CHEMBL99516S-8510 is a BZD partial inverse agonist to the BZD site on the GABA-A receptors in the central nervous system. As an inverse agonist (which as a group elicit CNS effects such as insomnia, agitation, and proconvulsant behaviors), S-8510 functions as a negative modulator of the GABA-A receptor. S-8510, however, is a partial inverse agonist, which means it has a lower affinity for the BZD binding site than do full agonists, and studies in animals have shown that the drug does not induce convulsions or anxiety.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…